Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy.
Finsterer
Josef
J
Stöllberger
Claudia
C
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D015992:Body Mass Index; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D002986:Clinical Trials as Topic / Q000379:methods* / Q000592:standards*; D004452:Echocardiography / Q000379:methods / Q000592:standards; D006352:Heart Ventricles / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008297:Male; D020388:Muscular Dystrophy, Duchenne / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D017063:Outcome Assessment, Health Care / Q000379:methods* / Q000592:standards*; D015203:Reproducibility of Results; D012131:Respiratory Insufficiency / Q000453:epidemiology
D000305:Adrenal Cortex Hormones; D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors